RT Journal Article
SR Electronic
T1 Lack of evidence for interactions between <em>APOE</em> and <em>Klotho</em> genotypes on cognitive, dementia and brain imaging metrics in UK Biobank
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.11.20248318
DO 10.1101/2021.01.11.20248318
A1 Tank, Rachana
A1 Ward, Joey
A1 Smith, Daniel J.
A1 Flegal, Kristin E.
A1 Lyall, Donald M.
YR 2021
UL http://medrxiv.org/content/early/2021/01/15/2021.01.11.20248318.abstract
AB Importance Recent research has suggested that genetic variation in the Klotho (KL) locus may modify the association between apolipoprotein e (APOE) e4 genotype and cognitive impairment.Objective Large-scale testing for associations and interactions between KL and APOE genotypes vs. risk of dementia (n=1,570 cases), cognitive abilities (n=174,513) and brain structure (n = 13,158) in older (60+ years) participants.Design, setting and participants Cross-sectional and prospective data (UK Biobank).Main outcomes and measures KL status was indexed with heterozygosity of the rs9536314 polymorphism (vs. not), in unrelated people with vs. without APOE e4 genotype, using regression and interaction tests. We assessed non-demented cognitive scores (processing speed; reasoning; memory; executive function), multiple structural brain imaging, and clinical dementia outcomes. All tests were corrected for age, sex, assessment centre, eight principal components for population stratification, genotypic array, smoking history, deprivation, and self-reported medication history.Results APOE e4 presence (vs. not) was associated with increased risk of dementia, worse cognitive abilities and brain structure differences. KL heterozygosity was associated with less frontal lobe grey matter. There were no significant APOE/KL interactions for cognitive, dementia or brain imaging measures (all P&gt;0.05).Conclusions and relevance We found no evidence of APOE/KL interactions on cognitive, dementia or brain imaging outcomes. This could be due to some degree of cognitive test imprecision, generally preserved participant health potentially due to relatively young age, type-1 error in prior studies, or indicative of a significant age-dependent KL effect only in the context of marked AD pathology.Key pointsQuestion: Klotho genotype has been previously shown to ‘offset’ a substantial amount of the APOE e4/cognitive impairment association. Is this modification effect apparent in large-scale independent data, in terms of non-demented cognitive abilities, brain structure and dementia prevalence?Findings: In aged 60 years and above participants from UK Biobank, we found significant associations of APOE and Klotho genotypes on cognitive, structural brain and dementia outcomes, but no significant interactions.Meaning: This could reflect somewhat healthy participants, prior type 1 error or cognitive/dementia ascertainment imprecision, and/or that Klotho genotypic effects are age and neuropathology dependent.Competing Interest StatementThe authors have declared no competing interest.Funding StatementRT is funded by a Baillie Gifford doctoral student fellowship.UK Biobank was established by the Wellcome Trust medical charity, Medical Research Council, Department of Health, Scottish Government and the Northwest Regional Development Agency. It has also had funding from the Welsh Assembly Government and the British Heart Foundation. DJS is supported by an MRC Pathfinder grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Participants provided full informed consent to participate in UK Biobank. This study was covered by the generic ethical approval for UK Biobank studies from the NHS National Research Ethics Service (approval letter dated 17th June 2011, Ref 11/NW/0382). Approval was received from UK Biobank to use the data in the present work (UK Biobank application #17689; PI Lyall).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe UK Biobank resource is available to bona fide researchers for health-related research in the public interest. All researchers who wish to access the research resource must register with UK Biobank (https://www.ukbiobank.ac.uk). Analytic scripts are available upon request. https://www.ukbiobank.ac.uk/enable-your-research/register